These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 7608256

  • 1. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects.
    Beldjord C, Desclaux-Arramond F, Raffin-Sanson M, Corvol JC, De Keyzer Y, Luton JP, Plouin PF, Bertagna X.
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256
    [Abstract] [Full Text] [Related]

  • 2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P.
    Verh Dtsch Ges Pathol; 1995 Jul; 79():L-LV. PubMed ID: 8600671
    [Abstract] [Full Text] [Related]

  • 3. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B.
    Maruyama S, Iwashita T, Imai T, Funahashi H, Ceccherini I, Luo Y, Romeo G, Matsuo S, Matsuyama M, Takahashi M.
    Jpn J Cancer Res; 1994 Sep; 85(9):879-82. PubMed ID: 7961113
    [Abstract] [Full Text] [Related]

  • 4. Mutations in the RET protooncogene in sporadic pheochromocytomas.
    Lindor NM, Honchel R, Khosla S, Thibodeau SN.
    J Clin Endocrinol Metab; 1995 Feb; 80(2):627-9. PubMed ID: 7852530
    [Abstract] [Full Text] [Related]

  • 5. The RET proto-oncogene and cancer.
    Donis-Keller H.
    J Intern Med; 1995 Oct; 238(4):319-25. PubMed ID: 7595167
    [Abstract] [Full Text] [Related]

  • 6. The RET proto-oncogene in sporadic pheochromocytomas.
    Takaya K, Yoshimasa T, Arai H, Tamura N, Miyamoto Y, Itoh H, Nakao K.
    Intern Med; 1996 Jun; 35(6):449-52. PubMed ID: 8835594
    [Abstract] [Full Text] [Related]

  • 7. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
    Landsvater RM, Jansen RP, Hofstra RM, Buys CH, Lips CJ, Ploos van Amstel HK.
    Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
    [Abstract] [Full Text] [Related]

  • 8. Absence of mutations at codon 768 of the RET proto-oncogene in sporadic and hereditary pheochromocytomas.
    Yoshimoto K, Kimura T, Tanaka C, Moritani M, Iwahana H, Itakura M.
    Endocr J; 1996 Feb; 43(1):109-14. PubMed ID: 8732460
    [Abstract] [Full Text] [Related]

  • 9. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
    Pausova Z, Soliman E, Amizuka N, Janicic N, Konrad EM, Arnold A, Goltzman D, Hendy GN.
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2711-8. PubMed ID: 8675600
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Frequent RET protooncogene mutations in multiple endocrine neoplasia type 2A.
    Quadro L, Panariello L, Salvatore D, Carlomagno F, Del Prete M, Nunziata V, Colantuoni V, Di Giovanni G, Brandi ML, Mannelli M.
    J Clin Endocrinol Metab; 1994 Aug; 79(2):590-4. PubMed ID: 7913936
    [Abstract] [Full Text] [Related]

  • 12. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2.
    Ponder BA.
    Cancer Surv; 1995 Aug; 25():195-205. PubMed ID: 8718519
    [No Abstract] [Full Text] [Related]

  • 13. Absence of mutations in the MEN2A region of the ret proto-oncogene in non-MEN 2A phaeochromocytomas.
    Chew SL, Lavender P, Jain A, Weber A, Ross RJ, Wass JA, Besser GM, Clark AJ.
    Clin Endocrinol (Oxf); 1995 Jan; 42(1):17-21. PubMed ID: 7889627
    [Abstract] [Full Text] [Related]

  • 14. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A, Roth J, Heitz PU.
    Cancer; 1995 Aug 01; 76(3):479-89. PubMed ID: 8625130
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
    Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A.
    Hum Mol Genet; 1994 Feb 01; 3(2):237-41. PubMed ID: 7911697
    [Abstract] [Full Text] [Related]

  • 17. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
    Oishi S, Sato T, Takiguchi-Shirahama S, Nakamura Y.
    Endocr J; 1995 Aug 01; 42(4):527-36. PubMed ID: 8556060
    [Abstract] [Full Text] [Related]

  • 18. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer.
    Blaugrund JE, Johns MM, Eby YJ, Ball DW, Baylin SB, Hruban RH, Sidransky D.
    Hum Mol Genet; 1994 Oct 01; 3(10):1895-7. PubMed ID: 7849720
    [No Abstract] [Full Text] [Related]

  • 19. Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland.
    Padberg BC, Schröder S, Jochum W, Kastendieck H, Roth J, Heitz PU, Komminoth P.
    Am J Pathol; 1995 Dec 01; 147(6):1600-7. PubMed ID: 7495285
    [Abstract] [Full Text] [Related]

  • 20. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M, Jackson CE, Feldman GL.
    Hum Mutat; 1996 Dec 01; 8(1):64-70. PubMed ID: 8807338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.